Cargando…
Longitudinal examination of perfusion and angiogenesis markers in primary colorectal tumors shows distinct signatures for metronomic and maximum-tolerated dose strategies()
Metronomic chemotherapy (MET) has been developed to address the shortcomings of maximum-tolerated chemotherapy (MTD) in regard to toxicity and development of resistance mechanisms in the tumor. In colorectal cancer (CRC), MET is a promising novel strategy to treat locally advanced malignancies when...
Autores principales: | Mundo, Ariel I., Muhammad, Abdussaboor, Balza, Kerlin, Nelson, Christopher E., Muldoon, Timothy J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326335/ https://www.ncbi.nlm.nih.gov/pubmed/35901621 http://dx.doi.org/10.1016/j.neo.2022.100825 |
Ejemplares similares
-
Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens
por: Tank, Anup, et al.
Publicado: (2020) -
Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers
por: Schito, Luana, et al.
Publicado: (2020) -
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer
por: Bazzola, L, et al.
Publicado: (2015) -
Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis
por: ALBERTSSON, PER, et al.
Publicado: (2012) -
Metronomic chemotherapy
por: Maiti, Rituparna
Publicado: (2014)